Abeona Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Ohio, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
6555 Carnegie Ave Fl 4, Cleveland, Ohio,...Phone Number
(646) 813-4701Website
www.abeonatherapeutics.comRevenue
$14.5 MillionStock Symbol
ABEOIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About Abeona Therapeutics
Abeona Therapeutics Inc. is a publicly traded, commercial-stage biopharmaceutical company headquartered in Cleveland, Ohio, and listed on the NASDAQ under the ticker ABEO. Formerly known as PlasmaTech Biopharmaceuticals, the company develops and commercializes cell and gene therapies for serious rare diseases. Its lead product, ZEVASKYN (prademagene zamikeracel), is an FDA-approved autologous, cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). Abeona also maintains a pipeline of AAV-based gene therapies targeting ophthalmic diseases, supported by its proprietary AIM Vector Platform of next-generation AAV capsids. The company operates a fully integrated cGMP manufacturing facility in Cleveland, Ohio.Explore more
Abeona Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Abeona Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Abeona Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Abeona Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Abeona Therapeutics
Check out if Abeona Therapeutics is spiking on competitors!
Click to see if Abeona Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Abeona Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Abeona Therapeutics launches new products
Abeona Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Abeona Therapeutics
Compare insights from companies similar to Abeona Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Abeona Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Abeona Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Abeona Therapeutics.
Abeona Therapeutics financials insights
Gather financial insights about Abeona Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Other Financing Round
$3.6M
2015
Share Placement
$8.5M
2017
Grant
$13.8M
Share Placement
$92M
2019
Stock Offering
$103.5M
2020
Debt
$1M
2022
Other Financing Round
$35M
2023
Share Placement
$25M
Abeona Therapeutics Tech Stack
A closer look at the technologies used by Abeona Therapeutics
Most Recent Scoops
Person-Based
Medical Research
Project
Abeona Therapeutics has reported that approximately 60% of patients are covered by commercial insurance and approximately 30% to 35% are Medicaid patients, with in-state Medicaid representing the fastest authorization pathway and out-of-state Medicaid the slowest.
Medical Administration
Project
Abeona Therapeutics has reported that approximately 20% of identified ZEVASKYN patient candidates are actively pursuing treatment, with identified patients defined as those with large chronic wounds prioritized by physicians as immediate candidates.
Medical Research
Project
Abeona Therapeutics has reported that Medicaid coverage across all 50 states and that more than 95% of commercial insurance coverage policies have been published, with no final payer denials recorded to date.
Project
Capacity Planning, Manufacturing Operations
Abeona Therapeutics News & Media
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, June 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
CLEVELAND, May 26, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in June 2026:Abeona Therapeutics Inc. (ABEO) Q1 2026 Earnings Call Transcript
Abeona Therapeutics Inc. (ABEO) Q1 2026 Earnings Call May 13, 2026 8:30 AM EDTCompany ParticipantsJoseph Vazzano - Chief Financial OfficerVishwas Seshadri -...Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update
- Three patients treated with ZEVASKYN® in Q1 2026 -
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Abeona Therapeutics
Sign Up For FreeTo access detailed company insights
Abeona Therapeutics Inc. is a publicly traded, commercial-stage biopharmaceutical company headquartered in Cleveland, Ohio, and listed on the NASDAQ under the ticker ABEO. Formerly known as PlasmaTech Biopharmaceuticals, the company develops and commercializes cell and gene therapies for serious rare diseases. Its lead product, ZEVASKYN (prademagen... Read More
